Compare CCSI & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCSI | EVMN |
|---|---|---|
| Founded | 2021 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 443.8M | 529.6M |
| IPO Year | N/A | 2025 |
| Metric | CCSI | EVMN |
|---|---|---|
| Price | $26.35 | $28.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $33.50 | ★ $44.17 |
| AVG Volume (30 Days) | 244.2K | ★ 1.1M |
| Earning Date | 02-09-2026 | 06-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.35 | N/A |
| Revenue | ★ $349,696,000.00 | $13,000,000.00 |
| Revenue This Year | $2.85 | $89.43 |
| Revenue Next Year | $0.30 | N/A |
| P/E Ratio | $5.57 | ★ N/A |
| Revenue Growth | N/A | ★ 160.00 |
| 52 Week Low | $17.84 | $13.89 |
| 52 Week High | $30.08 | $33.20 |
| Indicator | CCSI | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 70.70 | 69.63 |
| Support Level | $22.16 | $15.97 |
| Resistance Level | $23.90 | $33.20 |
| Average True Range (ATR) | 1.14 | 3.01 |
| MACD | 0.44 | 0.89 |
| Stochastic Oscillator | 93.45 | 74.55 |
Consensus Cloud Solutions Inc is a provider of secure information delivery services with a scalable Software-as-a-Service SaaS platform. It is engaged in fax cloud business. The Company operates in USA, Canada, Ireland, and Other. Geographically, it derives a maximum revenue from the United States. The company's communication and digital signature solutions enable customers to securely and cooperatively access, exchange and use information across organizational, regional, and national boundaries.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.